ALIM:NSD-Alimera Sciences, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 4.69

Change

-0.02 (-0.42)%

Market Cap

USD 0.02B

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia. Address: 6120 Windward Parkway, Alpharetta, GA, United States, 30005

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-30 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-0.20 (-0.69%)

USD10.78B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

+0.38 (+4.49%)

USD3.00B 29.51 N/A
PCRX Pacira BioSciences, Inc

-3.21 (-5.03%)

USD2.77B 21.77 59.76
APHA Aphria Inc

+0.65 (+8.41%)

USD2.25B 25.85 454.68
IRWD Ironwood Pharmaceuticals, Inc

-0.31 (-2.62%)

USD1.89B 16.92 14.02
ATNX Athenex, Inc

-0.30 (-2.15%)

USD1.30B N/A N/A
ENDP Endo International plc

-0.31 (-5.75%)

USD1.24B N/A 9.49
SUPN Supernus Pharmaceuticals, Inc

-0.57 (-2.61%)

USD1.15B 9.07 5.57

ETFs Containing ALIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.13% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.13% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -31.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.33% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -89.58% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.58% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.83% N/A N/A 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.83% N/A N/A 5% F
Risk Return Profile  
Volatility (Standard Deviation) 25.48% N/A N/A 58% F
Risk Adjusted Return -113.15% N/A N/A 2% F
Market Capitalization 0.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.13 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -5.87 N/A N/A N/A N/A
EV/EBITDA 22.72 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -14.68% N/A N/A N/A N/A
Return on Assets 0.98% N/A N/A N/A N/A
Debt to Equity Ratio -869.70% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.52 N/A N/A N/A N/A
Short Percent 0.46% N/A N/A N/A N/A
Beta 1.86 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.